Istradefylline

伊曲茶碱

Report date: 2022/01/14 13:23:58
NMEFirst In Class

Base Information

Drug NameIstradefylline
Drug Alias NameistradefilinaistradefyllinumNourianzNouriastKW-6002
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdenosine A2a receptor antagonists
TargetsAdenosine A2a receptor
Therapy Area/IndicationsCognition DisordersSubstance-Related DisordersSleep Wake Disorders +[8] 
Global Approved IndicationsParkinson Disease
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2013/03/25
Country/TerritoryCzechiaCanadaUnited States +[12] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesKyowa Hakko Kirin Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesKyowa Kirin IncKyowa KirinKyowa Hakko Kirin Co Ltd +[6] 
Inactive CompaniesKyowa Hakko Kirin Pharma IncKyowa Kirin Co LtdThe University Of Chicago +[7] 
Active IndicationsCognition DisordersAmyotrophic Lateral SclerosisParkinson Disease
Inactive IndicationsSubstance-Related DisordersSleep Wake DisordersRestless Legs Syndrome +[5] 

Other Information

ATC CodeN04B
Related LinksWikipediaKEGG